Correlation between SMARCB1/INI1 expression and different molecular markers. (A) CDX2, vimentin, p53 and SMARCB1/INI1 immunostaining profile in a poorly differentiated tumor (a-d). (B) The SMARCB1/INI1 expression profile is divided into three categories Neg, Low and High and correlated with CDX2 and vimentin expression pattern in tumor cells. (C) The same analysis takes into account p53 expression and the CpG island methylator phenotype (CIMP) status. Tumors with at least three methylated markers (RUNX3, IGF2, SOCS1, NEUROG1, CDKN2A and hMLH1) were classified as CIMP-positive, the remaining as CIMP-negative. The p value is reported in each graph.